Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures
Paul Thoueille, Matthias Cavassini, Monia Guidi, Thierry Buclin, François Girardin, Laurent A. Décosterd, Catia Marzolini
Abstract
The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations.
Topics & Concepts
RilpivirineMedicineTherapeutic drug monitoringDrugPharmacologyIntensive care medicineHuman immunodeficiency virus (HIV)VirologyViral loadAntiretroviral therapyHIV/AIDS drug development and treatmentHepatitis C virus researchHIV Research and Treatment